Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799061 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL13812182 | 0.90 | ALDH1A1 (0.34) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL13799060 | 0.89 | KDM4E (0.43) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL335129 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL13799059 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL4397020 | 0.87 | KDM4E (0.44) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3812752 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10243304 | 0.84 | KDM4E (0.42) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3809966 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL4392698 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628990-B1 | NOVEL 14 AND 15 MEMBERED RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| US-20080221158-A1 | Novel 14 and 15 Membered Ring Compounds | PLIVA - Istrazivacki Institut d.o.o | 2008-09-11 | — | — | US | disclosed |
| US-7351696-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-01 | — | — | US | disclosed |
| EP-1633765-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | GLAXO GROUP LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070141276-A1 | Novel 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070037757-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037757-A1 | Compounds | FPR1, TSLP, TLR5 | KDM4E 3706/4885ALDH1A1 131/4885LMNA 3262/4885 |
| US-20080221158-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | KDM4E 3036/4885ALDH1A1 1819/4885LMNA 4115/4885 |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | KDM4E 2612/4885ALDH1A1 2370/4885LMNA 2596/4885 |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | IL17A, IL15, CASP14 | KDM4E 1422/4885ALDH1A1 3802/4885LMNA 3341/4885 |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | IL4, CYP51A1, IL17A | KDM4E 1543/4885ALDH1A1 2288/4885LMNA 2144/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | KDM4E 620/4885ALDH1A1 3491/4885LMNA 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.